← Back to patent-cliff list
18F-OP-801
Tier C — Watch / trade18F-OP-801
Ashvattha Therapeutics
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Updating
Indications (approved)：Alzheimer's disease, Multiple sclerosis, Amyotrophic lateral sclerosis, Parkinson's disease
Regional status
US
Phase II
2023-02-02
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of 18F-OP-801?
Approved indications include: Alzheimer's disease, Multiple sclerosis, Amyotrophic lateral sclerosis, Parkinson's disease.
When does the 18F-OP-801 patent expire?
No public expiry year is available for 18F-OP-801 yet; this page updates once verified.
How do I get a quote for 18F-OP-801 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-03